Healthcare technologies gain regulatory and clinical-use milestones, with evidence gaps remaining

Edwards’ PASCAL Precision is FDA-approved for high-risk patients with severe symptomatic tricuspid regurgitation, while Teleflex’s Freesolve has Breakthrough Device Designation rather than approval. Novo Nordisk’s weekly insulin icodec gained FDA approval for children aged 10 and older with type 2 diabetes, but pediatric support relied on pharmacokinetics plus adult data. A small uncontrolled knee-injection study is another clinical signal, not proof of broad effectiveness; pivotal evidence, real-world outcomes, and access remain important.